1. <source id="c6bcq"><nav id="c6bcq"><strike id="c6bcq"></strike></nav></source>
      1. <rp id="c6bcq"><nav id="c6bcq"><button id="c6bcq"></button></nav></rp>
        <rt id="c6bcq"><nav id="c6bcq"><button id="c6bcq"></button></nav></rt>

        <rt id="c6bcq"><meter id="c6bcq"><button id="c6bcq"></button></meter></rt>
      2. A POWERFUL RESEARCH AND
        DEVELOPMENT ENGINE

        Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.

        • Phase 1 trials

          Phase 1 Trials

          CEMIPLIMAB*

          PD-1 Antibody
          Cancer

          REGN1979

          CD20 X CD3 Antibody
          Cancer

          CEMIPLIMAB + REGN1979

          PD-1 Antibody + CD20 X CD3 Antibody
          Cancer

          REGN3767

          LAG-3 Antibody
          Cancer

          CEMIPLIMAB + REGN3767

          PD-1 Antibody + LAG-3 Antibody
          Cancer

          REGN5458*

          BCMA X CD3 Antibody
          Cancer

          REGN4018*

          MUC16 X CD3 Antibody
          Cancer

          CEMIPLIMAB + REGN4018*

          PD-1 Antibody + MUC16 X CD3 Antibody
          Cancer

          REGN4659

          CTLA4 Antibody
          Cancer

          REGN3048-3051

          Middle Eastern Respiratory Coronavirus Antibody
          MERS-CoV infection

          POZELIMAB

          C5 Antibody
          Paroxysmal nocturnal hemoglobinuria

          REGN4461

          LEPR Antibody
          Lipodystrophy and obesity

          REGN5069

          GFRα3 Antibody
          Pain
        • Phase 2 trials

          Phase 2 Trials

          CEMIPLIMAB*

          PD-1 Antibody
          Basal cell carcinoma

          DUPILUMAB*

          IL-4R Antibody
          Grass allergy, peanut allergy

          SARILUMAB*

          IL-6R Antibody
          Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

          EVINACUMAB

          ANGPTL-3 Antibody
          Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

          REGN1908-1909

          Fel d 1 Antibody
          Cat allergy

          GARETOSMAB

          Activin A Antibody
          Fibrodysplasia Ossificans Progressiva (FOP)

          REGN3500*

          IL-33 Antibody
          Atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD)
        • Phase 3 trials

          Phase 3 Trials

          ALIROCUMAB*

          PCSK9 Antibody
          Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

          CEMIPLIMAB*

          PD-1 Antibody
          Non-small cell lung cancer, cervical cancer

          DUPILUMAB*

          IL-4R Antibody
          Atopic dermatitis in pediatrics, asthma in pediatrics, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD)

          SARILUMAB*

          IL-6R Antibody
          Polymyalgia rheumatica, giant cell arteritis

          EVINACUMAB

          ANGPTL-3 Antibody
          Homozygous familial hypercholesterolemia (HoFH)

          REGN-EB3 (REGN3470-3471-3479)

          Ebola Virus Antibody
          Ebola virus infection

          FASINUMAB?

          NGF Antibody
          Chronic pain from osteoarthritis of the knee or hip

        Trials Footnotes

        * in collaboration with Sanofi

        ? in collaboration with Teva and Mitsubishi Tanabe

        This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

        紫夜影视网